Transcatheter aortic valve replacement Randomized control trials
1.

Introduction
Degenerative aortic stenosis (AS) is the one of the most commonly acquired valvular heart disease in aging adults. 1 In patients with symptomatic AS, surgical aortic valve replacement (SAVR) has been the treatment of choice for over 4 decades. The overall mortality for isolated AVR ranges from 2.5e4.0%. 2e4 However, it is estimated that roughly 30e60% of the patients with symptomatic AS are deemed "high-risk" for conventional AVR 4e6 and may be denied open-heart surgery.
Rapid advancements in transcatheter technology led to the innovation of transcatheter aortic valve replacement (TAVR).
Recently, there has been a rapid surge in the utilization of TAVR to treat high-risk patients with severe symptomatic AS. The rapid worldwide dissemination of this new technique carries the hazard that patients who are candidates for conventional SAVR would be treated percutaneously. The "offlabel" use of TAVR has been estimated to be as high as 67% in some centers. 7 Currently, there are two device types available for TAVR: balloon expandable Edwards valve (Edwards Lifesciences, USA) and the self-expanding CoreValve system (Medtronic, Inc, USA).
The multicenter randomized controlled Placement of Aortic Transcatheter Valves (PARTNER) trial has demonstrated similarity of SAVR and TAVR with respect to mortality, reduction in symptoms and improvement in valve hemodynamics, up to two years of follow up.
8e11 While robust clinical evidence emanating from rigorously conducted randomized trials is a cornerstone of premarket conformity assessment process, it is of paramount importance to recognize the shortcomings of these premarket clinical assessments. The follow-up is still limited, the study populations are pre-selected. Further, the initial sites for the clinical trial typically consisted of large academic centers with tremendous oversights. As formal post-marketing surveillance programs will be instituted, outcomes data from multicenter and/or national registries will become increasingly important. This review summarizes and compares the data from US randomized trial to these multi center registries outside of US. 12, 13 The earliest experience with the CoreValve was reported in the multicenter expanded evaluation registry comprising experience between 2007 and 2008. 14 Till date, several multicenter registries of TAVR have been assembled and described. 12e22 These registries provide the results after commercialization of the available devices and reflect real-world experience, with the exception of US. Table 1 describes the characteristics of 11 large representative registries that have been described in the literature along with the two cohorts of the PARTNER trial. Of these 11 registries, 3 have exclusively described CoreValve experience, 14,17,22 3 have exclusively described Edwards valve experience 12, 13, 16 and the rest have reported combined experiences with both valves. 15,18e22 Transfemoral approach seemed to be the favored approach in most registries and was adopted in 46.9e95.8% of all reported cases. i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 4 0 0 e4 1 1 PARTNER trial reported outcomes with the Edwards balloon expandable valve in two different cohorts: Cohort A comprised of high-risk patients with AS who were randomized to TAVR or SAVR 9, 11 ; cohort B comprised of inoperable AS patients who were randomized to TAVR or standard therapy including balloon aortic valvuloplasty. 8, 10 Table 2 demonstrates the baseline characteristics of patients included in individual multicenter registries and the PARTNER trial cohorts. The mean age in all registries was consistently greater than 80 years and the proportion of males varied from 44.0e59.3%. There was a significant heterogeneity in the risk profile of patients in various registries. The lowest risk profile was reported in the Australian New Zealand registry reporting a mean (SD) logistic EuroSCORE of 18.4 (11.9)%. 17 In addition to this registry, the UK-TAVI registry also had similar risk profile patients with a median (IQR) logistic EuroSCORE of 18.5 (11.7e27.9)%. 18 On the contrary, the other registries had mean logistic EuroSCORE > 20%. The highest risk patients were reported in the PARTNER-EU registry with mean (SD) logistic EuroSCORE of 30.0 (13.7%). 16 The mean (SD) logistic EuroSCORE in the PARTNER cohort A and cohort B patients undergoing TAVR was 29.3 (16.5) and 26.4 (17.2), respectively. 8, 9 With the due consideration of the logistic EuroSCORE in the decision making for TAVR, it is important to remember that a large proportion of patients are refused for SAVR and undergo TAVR on the basis of risk factors such as frailty or porcelain aorta, neither of which are a part of traditional surgical risk calculators.
Multicenter registries and randomized control trials for TAVR
TAVR
Procedural success
The procedural success in the representative registries has varied from 88.5e98.4% [ Fig. 1 ]. Although procedural success was not formally defined in the PARTNER trial, the transcatheter closure was either aborted or could not be performed in 4.6% and 3.4% of patients in cohort A and B, respectively. There are several reasons for a wide range for procedural success across various registries. Firstly, there was a difference in the definition of "Procedural Success" across the various registries. Secondly, the registries represent the different time periods in the development of TAVR technology. In addition, the learning curve phenomenon might have some negative influence on the procedural success rates. Most of the contemporary registries describe Fig. 1 e Procedural success across various registries. Although procedural success was not formally defined in the PARTNER trial, the transcatheter closure was either aborted or could not be performed in 4.6% and 3.4% of patients in cohort A and cohort B respectively. pooled outcomes from all the aspects of the learning phase including patient selection and imaging as well as procedural expertise and development of bailout strategies. However, in the more recent experience with the new valve types and delivery systems, the procedural success rates as well as the efficacy rates have improved and we can expect even better procedural outcomes in the coming years.
Mortality
The pooled incidence of all-cause mortality and cardiovascular related mortality across various multicenter registries and the PARTNER cohorts is demonstrated in Fig. 2 . The pooled 30-day all-cause mortality rate (95% CI) in the multicenter registries was estimated as 9.2 (7.8e10.5)%. On the other hand, the pooled 30-day all-cause mortality rate in the PARTNER trial cohorts was estimated to be significantly lower [3.8 (2.2e5.5)%]. Several factors may have contributed to the lower 30-day mortality rates in the PARTNER trial. All patients that were enrolled in the PARTNER trial underwent a rigorous preprocedural assessment and an extensive procedural planning in order to avoid any unforeseen complications. The trial sites included the best valve centers with very good infrastructure for the procedure. Finally, there might be societal and cultural differences in how complications were managed in this very elderly population in the US compared to outside US. Despite the differences in 30-day mortality rates observed between the multicenter registries and the PARTNER cohorts, the pooled 1-year all-cause mortality rates were similar between the two groups [ Fig. 3 ]. This highlights the fact that procedural mortality is important but the patient selection is probably more important in these patients because there is a considerable risk of mortality in the first year even after the successful procedure. The pooled one-year mortality rates (95% CI) in the multicenter registries and the PARTNER trial cohorts was estimated as 22.9 (19.0e26.9)% and 26.9 (20.7e33.2)%, respectively. Only two registries have published data for follow up longer than one year. 20, 23 The two-year mortality rate was observed to be 26.3% and 30.3% in the UK-TAVI and the Italian registries, respectively. 18, 22 The 3-year mortality rate has been reported to be 34.8% in the Italian registry. 24 The 2-year mortality rates in the PARTNER cohort A and cohort B have been observed to be 33.9% and 43.3%, respectively.
10,11
The distribution of cardiovascular related deaths is particularly interesting (Fig. 3) . A large majority of all deaths occurring within 30 days period after TAVR are procedure related cardiovascular deaths. However, this proportion of majority shifts rather quickly. At one-year follow up, a significant proportion of all deaths happened due to noncardiovascular causes. The pooled 30-day cardiovascular mortality rate (95% CI) in the multicenter registry and the PARTNER trial cohorts was estimated as 7.0 (5.9e8.1)% and 3.6 (2.0e5.1)%, respectively. At one-year, cardiovascular mortality rate (95% CI) was estimated to be 13.4 (9.6e17.2)% and 16.5 (11.4e21.6)% in the registry and the trial arm, respectively.
In the FRANCE 2 registry, the incidence of all-cause mortality and non-cardiovascular mortality at one year were reported to be 24.0% and 9.7%, respectively. 15 Similarly, in the
Belgian registry, about 65% of all deaths at one-year follow up were attributable to non-cardiovascular causes. 19 The results are equally striking at the two-year and three-year follow up reported in the Italian registry. 24 Roughly 60% of the all deaths occurring at two-year and three-year follow-up intervals were attributable to non-cardiovascular causes. 24 Most of these patients die as a result of co-morbidities or secondary to conditions associated with advanced age. One could argue, that since a significant proportion of patients die due to noncardiovascular causes, almost half of these patients should be denied TAVR in accordance with the 2008 European position statement on TAVR, which stated that this procedure should not be performed on patients with a life-expectancy < 1 year. 25 In the future, it would be crucial to identify patient population that is likely to derive the most advantage from application of TAVR technology, in the perspective of costeffectiveness. In an analysis performed by Ussia et al, it was suggested that although there was no significant difference in cardiovascular mortality between the moderate risk and the i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 4 0 0 e4 1 1 high-risk cohorts, there was a significant difference in the non-cardiovascular mortality in the high-risk population. 24 This would indirectly suggest that application of TAVR technology to lower-risk groups might demonstrate improved cardiovascular survival and quality of life with an added advantage of a lower non-cardiovascular related mortality.
Stroke
The pooled 30-day and 1-year stroke rate obtained from multicenter registries was estimated to be 2.6 (1.9e3.2)% and 3.8 (2.3e5.3)%, respectively [ Fig. 4 ]. Only a few registries have reported stroke rates upon medium-term follow-up. Although, the incidence rate of major stroke is consistent between several European registries, there appears to be a discrepancy in the rates between the registry data and the PARTNER trial. 8e11 In the cohort A of the PARTNER trial, there was a higher rate of neurological events, of which 40% occurred between 1 month and 1 year after the procedure. 9 The pooled 30-day and 1-year stroke rates in the PARTNER trial were estimated to be 5.2 (3.3e7.1)% and 7.6 (3.7e11.4)%, respectively. There are several possible explanations for these discrepant findings. 9 Firstly, the prevalence of pre-existing cerebrovascular disease (w30%) in the PARTNER trial could play a role in the higher incidence of stroke in the trial as compared to the registry data. Secondly, the devices used were first generation devices and that may be responsible for somewhat higher stroke rates. Thirdly, and most importantly all patients underwent neurologic examination and NIH scoring before the procedure and at discharge from the hospital by trained personnel. Moreover, the diagnosis of stroke was adjudicated by CEC in the PARTNER trial as compared to cardiologists and anesthesiologists assessing neurological function after TAVR in most registries. This may result in underestimation of clinically relevant neurological events in the registry-derived data. Magnetic resonance imaging (MRI)based studies have demonstrated cerebral perfusion defects in approximately 70e80% of the patients undergoing TAVR. 26 Although majority of these patients are asymptomatic from a neurological standpoint, this 
highlights the need for a systematic assessment of neurological function including cognitive abilities. 26 
Post-procedure aortic regurgitation
Moderate/severe paravalvular aortic regurgitation (AR) has been shown to be associated with increased risk of death on follow-up. 15, 18 Whether the degree of AR is responsible for an early mortality or is merely a marker for adverse outcomes, is not currently clear. Although moderate/severe AR is infrequent after TAVR, mild paravalvular AR is encountered quite commonly. The clinical significance of mild paravalvular AR is under intense investigation. Small studies have demonstrated that there were no adverse effects of mild AR on left ventricular function at medium-term follow-up period. 27 On the contrary, a recently published meta-analysis demonstrated a trend toward an increased mortality even in patients with mild paravalvular AR. 28 This trend toward increased mortality with mild paravalvular AR was also observed in the 2-year follow up of the PARTER-A trial. 11 Echocardiographic follow up of 2-year survivors in the PARTNER-A trial demonstrated that the paravalvular AR improved in 42.6%, did not change in 41.0% and worsened in 16.4%. None of the patients in the TAVR group had AR that worsened to a moderate/severe degree during follow-up. With the adoption of TAVR for lowerrisk, younger individuals, there might be a lower tolerance toward mild paravalvular AR, requiring revisions in valve design to ensure flush circumferential annular apposition. Table 3 demonstrates the incidence of post-procedure AR upon short-term and medium-term follow-up. The pooled incidence (95% CI) of moderate or severe AR at 30 days after TAVR has been estimated to be 20.6 (13.4e27.8)% and 16.1 (9.4e22.9)% across the multicenter registries and the PARTNER trial cohorts, respectively. At 1-year follow up, the incidence of moderate or severe AR was estimated to be 19.9 (17.4e22.4)% and 7.5 (5.3e9.8)% across the multicenter registries and the PARTNER trial cohorts, respectively. The 2-year and 3-year follow up AR rates were reported to be 16.5% and 10.1% in the Italian CoreValve registry. 24 
7.
Arrhythmias, conduction abnormalities and pacemaker implantation Arrhythmias and conduction abnormalities are important concerns after TAVR. Although supraventricular and ventricular arrhythmias have been observed after TAVR at varying frequencies, they are encountered in roughly 20e30% of patients after SAVR and any valid comparison of frequency of arrhythmias between the two strategies would need to include a careful analysis of post-therapy arrhythmias. 29 The occurrence of new onset left bundle branch block after SAVR has been associated with an increased risk of death and subsequent life-threatening arrhythmias during follow up.
30,31
New onset intraventricular conduction abnormalities, particularly the new onset left bundle branch block are encountered frequently after TAVR (7e18% after Edwards valve implantation; 30e83% after CoreValve implantation). 23,29,32e35 Direct mechanical injury of the left bundle branch and the inflammation due to the stent prosthesis are likely offenders to the conduction system. However, the implications of a new onset left bundle branch block after TAVR upon long-term adverse outcomes are not well understood. In several instances, the conduction system abnormalities arising as a result of prosthetic valve placement necessitate the implantation of permanent pacemaker. Fig. 5 demonstrates the incidence of permanent pacemaker implantation in the Edwards valve and CoreValve cohorts. At 30-day follow-up period, the pooled incidence of permanent pacemaker implantation in the Edwards valve cohort and the CoreValve cohort in the multicenter registries was observed to be 7.6 (4.0e11.3)% and 25.7 (16.7e34.7)%, respectively. Among the Edwards valve cohorts, all registries except the German registry reported 30-day pacemaker implantation rate less than 10%. 20 On the other hand, among the CoreValve cohorts, all registries except the multicenter expanded evaluation registry and the Italian registry reported pacemaker implantation rate greater than 20%. Among the Edwards valve cohorts, the 1-year pacemaker implantation rate was reported to be 3.1% in the PARTNER-EU registry and 11.5% in the FRANCE 2 registry. 15, 16 Among the CoreValve cohorts, the 1-year pacemaker implantation rate was reported to be 19.1% in the Italian registry and 24.2% in the FRANCE 2 registry. 15, 22 The pooled incidence (95% CI) among the PARTNER cohorts, which utilized the Edwards balloon expandable valves, was calculated to be 3.7 (2.1e5.3)%. Among procedural variables, the use of CoreValve system and the deeper (ventricular) implantation of the valve prosthesis have been identified as the most important variables predicting the need for permanent pacemaker implantation. 36 The nitinol frame of the CoreValve system exerts a higher i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 4 0 0 e4 1 1 radial strength on the ventricular septum as compared to the stainless steel or cobalt chromium frame of the Edwards valve, leading to an increased risk of damage to the conduction system. Further, the length of the device also adds to the forces on the conduction system due to torsional motion of the aortic root and the angle between the left ventricular outflow and the ascending aorta. The impact of permanent pacemaker implantation on long-term outcomes has been poorly explored in patients undergoing TAVR. Table 4 demonstrates the vascular complications and bleeding events that may arise after TAVR. There is a significant heterogeneity in the definition and classification of bleeding and vascular complications. The VARC recommends classification of bleeding events as life-threatening, major and minor bleeding events. 37 The life-threatening and major bleeding event rates have ranged between 3.2% in the Italian CoreValve registry and 8.5% in the PARTNER-EU registry.
Vascular complications and other adverse events after TAVR
16,22
The incidence of major and minor vascular complications has ranged between 1.9e13.3% and 4.6e10.4%, respectively, across the various registries. The incidence of major vascular complications in the PARTNER cohort A and cohort B was 11.0% and 16.2%, respectively. 8, 9 The impact of vascular complication on mortality was more pronounced in the initial reports; but with increasing awareness, smaller devices and better bailout strategies, the impact of vascular complication on mortality is lower but in no ways insignificant.
Myocardial infarction
The incidence of MI at 30 days has ranged from 0 to 4.6% across the registries. The one-year incidence of MI in the multicenter registries has been observed to be between 1.2 and 6.2%. The variability in the MI rates stems from the lack of uniformity in the definition of periprocedural MI among the various TAVR registries. The pooled incidence (95% CI) of 30-day MI in the multicenter registries and the PARTNER trial was calculated to be 0.6 (0.2e1.1)% and 0 (0e0.4)% respectively. Similarly, the pooled incidence (95% CI) of oneyear MI in the multicenter registries and the PARTNER trial was calculated to be 1.7 (0.3e3.0)% and 0.5 (0e1.0)%, respectively.
Edwards valve versus CoreValve
Most of the contemporary data is derived from centers that do not perform both CoreValve and Edwards valve procedures, which is a significant limitation in drawing inferences about the comparison of two strategies. 
size as compared to 29 mm being the largest available Edwards valve. On the other hand, the Edwards valve has an advantage of a lower incidence of conduction abnormalities and need for permanent pacemaker implantation postprocedurally. Table 5 demonstrates the incidence rates of death, MI and stroke in patients undergoing TAVR stratified by the valve type. Among the Edwards valve cohorts, the 30-day incidence of death, MI and stroke ranged between 8.5 and 13.8%, 1.2e4.6% and 2.3e5.2%, respectively. Among the CoreValve a Only procedural rates available. 30-day event rate was not available.
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 4 0 0 e4 1 1 a Mean logistic EuroSCORE was not reported in this registry. Mean (SD) STS scores in the transapical cohort were 10.5 (6.9) % and 9.0 (5.8)% in the transapical and transfemoral TAVR cohorts respectively ( p ¼ 0.034). b Transapical TAVR outcomes not reported separately. The outcomes for "Other routes" were compared with those after transfemoral TAVR. c Median (interquartile range).
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 4 0 0 e4 1 1 cohorts, the 30-day incidence of death, MI and stroke ranged between 5.6 and 14.1%, 0e1.1% and 1.2e4.0%, respectively. The distribution of long-term all-cause mortality also appears to be similar between the two valve types across the available registries (Table 5 ).
11.
Transfemoral versus non-transfemoral approaches Table 6 demonstrates the incidence rates of all-cause mortality and stroke in the patients undergoing transfemoral and transapical TAVR. In the transfemoral cohorts of the multicenter registries, the pooled 30-day and 1-year mortality rates were observed to be 6.8 (5.3e8.4)% and 20.8 (18.9e22.8)%, respectively. In the transapical cohorts of the multicenter registries, the pooled 30-day and 1-year mortality rates were observed to be 12.2 (10.4e14.1)% and 32.2 (24.7e39.7)%, respectively. Among the PARTNER trial cohorts, the pooled incidence of 30-day and 1-year mortality rates were 3.9% and 26.2% in the transfemoral TAVR group and 3.8% and 29.0% in the transapical TAVR group. Several registries have reported significantly higher all-cause mortality among patients undergoing transapical TAVR as compared to those undergoing transfemoral TAVR. 19, 24, 25 The difference is likely secondary to the higher risk profile of the patients undergoing transapical TAVR as compared to the patients undergoing transfemoral TAVR. As is clearly evident in Table 6 , the logistic EuroSCORE in the transapical TAVR was consistently higher than that in the transfemoral cohort. Although inadequate peripheral vascular access is the most common reason for transapical approach, the transapical patients are higher risk individuals because of a systematic selection bias that has occurred with the delivery approach, especially across the multicenter registries. The selection bias results in a significantly higher prevalence of comorbidities in the transapical cohort; thereby, resulting in a higher short-term and medium-term mortality.
Long-term follow up studies
Surgically implanted aortic bioprostheses have shown 10-year freedom from prosthetic failure in the range of 60e90%, with younger patients predisposed toward premature deterioration. 38, 39 At 5 years, freedom from structural valve failure is generally greater than 95%. Although premature failure requiring repeat operation or leading to adverse clinical consequences has been described, freedom from repeat operation at 5 years is also generally greater than 95%. 38, 39 Whether TAVR can achieve similar outcomes remains to be seen. The data on long-term results following TAVR are rather scarce. Gurvitch et al reported a survival rate of 51% at 3-year follow-up in a cohort of 88 patients, who had undergoing TAVR with the Edwards valve in 2005e2006. 40 After discounting the patients who died within the first 30 days, the survival rates were 74% and 61% at 2-year and 3-year follow-up periods, respectively. 40 Besides this, the incidence of MI, stroke and pacemaker implantation at 3-year follow up was 8.6%, 8.6% and 7.1%, respectively. In the surviving patients who were in NYHA Class 3 and 4 at baseline, 85% Despite these preliminary data on long-term follow-up after TAVR, lack of large head-to-head comparisons between treatment strategies for AS (including TAVR) precludes definitive conclusions about long-term clinical outcomes.
Conclusions
The evidence derived from multicenter registries and the randomized trials has provided several unique insights. The data from the available multicenter registries have clearly demonstrated that patient selection would be the key to costeffective utilization of this revolutionary technology. The strength of data from the multicenter registries includes applicability to a large variety of patient population undergoing procedures in real-world settings across the world. On the other hand, the clinical trials help establish benchmarks for safety and efficacy related data, against which the real-world experiences may be compared. As seen in our review, the short-term results reported in the randomized trial appear to be better compared to those reported in the multicenter registries. This may be because of better patient selection, expert centers and more aggressive bailout techniques, which may have improved short-term results. Although the patient population was sicker in the PARTNER trial evidenced by a higher logistic EuroSCORE, the characterization of patients in the registries is less stringent. Although the PARTNER trial has provided thorough comparison of TAVR versus SAVR, it fails to provide the data regarding comparisons of available devices. These comparisons can be sought only from the experiences reported as a part of large multicenter registries. Both the Edwards valve and the CoreValve have demonstrated in improving symptoms and survival after TAVR in patients with severe AS. Other than the greater need for permanent pacemaker in patients undergoing CoreValve implantation, other outcomes for these devices have been comparable with minor differences. The comparison of transfemoral versus transapical approaches for TAVR has demonstrated superior outcomes for the former approach. However, the profile of patients undergoing transapical TAVR is significantly different with significantly greater comorbidities and a higher logistic EuroSCORE as compared to patients undergoing transfemoral TAVR.
One of the important differences between the outcomes of the PARTNER trial and the multicenter registries includes a significantly higher rate of stroke reported in the PARTNER trial. This could be attributed to a higher prevalence of pre-existing cerebrovascular disease in the PARTNER population. Moreover, the diagnosis of stroke was adjudicated by CEC in the PARTNER trial as compared to cardiologists and anesthesiologists assessing neurological function after TAVR in most registries. This might have resulted in underestimation of clinically relevant neurological events in the registry-derived data.
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 4 0 0 e4 1 1 The impact of co-morbid conditions like frailty, respiratory failure, pulmonary hypertension and severe mitral regurgitation on long-term outcomes following TAVR need to be definitively established. As the experience in TAVR implantation grows and the device design continues to improve in the coming years, one would hope that the technology would become available to lower-risk AS patients with equivalent or superior outcomes compared to conventional SAVR. At this time, off label use of TAVR should be vigorously avoided, given the good and predictable results of SAVR as well as the lack of robust long-term data about durability of TAVR. As the improvement of TAVR technology continues, registry data would be paramount in order to maintain and monitor efficacy and safety related outcomes in patients undergoing TAVR across the world.
